PYXS News and Press, Pyxis Oncology Inc.

BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effecti...

2024-06-10 05:54:47 ET Summary Pyxis Oncology develops innovative therapeutics for hard-to-treat cancers using antibody-drug conjugates and immunotherapies. The company's pipeline includes PYX-201 and PYX-106, targeting multiple solid tumor types, with preliminary data expected in...

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a...

2024-05-14 09:09:20 ET More on Pyxis Oncology Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait Pyxis Oncology gets $8M payment for sale of royalty rights Pyxis Oncology stock rises as it looks to raise $50M through a private placement ...

PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway i...

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a...

2024-04-12 17:05:37 ET Gainers: Applied Optoelectronics ( AAOI ) +5% . Eliem Therapeutics ( ELYM ) +4% . Infinera Corporation ( INFN ) +4% . Harrow ( HROW ) +4% . Health Catalyst ( HCAT ) +4% . Losers: Eagle Pharmaceutica...

2024-03-28 00:10:26 ET Summary Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. Initial data from the phase 1 trials of PYX-106 and PYX-201 are now expected in H2'24 and fall 2024 respectively. PYXS raised $50M in gross proceeds wit...

2024-03-27 17:44:47 ET More on Pyxis Oncology Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis Pyxis Oncology gets $8M payment for sale of royalty rights Read the full article on Seeking Alpha For further details see: Pyxis...

2024-03-27 07:43:03 ET More on Pyxis Oncology Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis Pyxis Oncology stock rises as it looks to raise $50M through a private placement Seeking Alpha’s Quant Rating on Pyxis Oncology ...